IRVINE, Calif.--(BUSINESS WIRE)--TherOx, Inc., a privately held medical device company focused on the treatment of Acute Myocardial Infarction (AMI), announced it completed enrollment in its multicenter Investigational Device Exemption (IDE) pilot study of a second generation system that delivers Supersaturated Oxygen (SSO2) Therapy for reduction of infarct size after an AMI. SSO2 Therapy is intended to provide interventional cardiologists with the first treatment option beyond percutaneous coronary intervention (PCI) to salvage heart muscle in heart attack patients.
Help employers find you! Check out all the jobs and post your resume.
